CTOs on the Move

Cohera Medical

www.coheramedical.com

 
Cohera Medical, Inc. is a rapidly growing medical device company actively developing surgical adhesives and sealants. TissuGlu Surgical Adhesive, the first synthetic adhesive approved for internal use, is an easily applied biocompatible, resorbable adhesive that requires no mixing or thawing. Indicated for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in abdominoplasty, TissuGlu Surgical Adhesive has been shown to eliminate the need for postoperative surgical drains in most abdominoplasty procedures.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cohera Medical raised $50M on 10/22/2015

Similar Companies

Healthcare Administrative Partners

Healthcare Admin Partner is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Healthcare Admin Partner is based in Media, PA. You can find more information on Healthcare Admin Partner at www.hapusa.com

KCAS Bioanalytical Labs

KCAS Bioanalytical Labs is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BZAM Cannabis

Headquartered in Vancouver, BC, BZAM Cannabis is a multi-licensed Canadian cannabis producer focused on branded consumer goods, cultivation, processing and people.

California Hospital Association

At California Hospital Association (CHA), we collaborate with our members to provide strong and effective representation and advocacy to advance the interests of California hospitals, patients and communities. CHA is a trusted resource, working with members to achieve legislative, regulatory, and legal accomplishments at the state and federal level. Based in Sacramento, CHA is the statewide leader representing the interests of more than 400 hospitals and health systems in California.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.